{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-023629","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.672667+00:00","generated_at":"2026-05-16T19:39:06.215900+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Elite Pharma Q2 FY2026 revenue $36.3M (+92% YoY); operating income $8.2M (+136% YoY)","bullets":["Consolidated revenue $36.3M for quarter ended Sept 30, 2025, up $17.4M or 92% vs prior year.","Income from operations $8.2M, up $4.7M or 136% YoY.","Growth driven by lisdexamfetamine product launches and strong Elite label product lines.","Conference call scheduled for Monday, Nov 17, 2025 at 11:30 AM EST."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-023629","json":"https://secwatch.observer/filing/0001493152-25-023629.json","markdown":"https://secwatch.observer/filing/0001493152-25-023629.md","text":"https://secwatch.observer/filing/0001493152-25-023629.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315225023629/0001493152-25-023629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315225023629/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:39:06.215900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}